Equity Overview
Price & Market Data
Price: $0.343
Daily Change: -$0.0017 / 0.50%
Daily Range: $0.336 - $0.345
Market Cap: $28,917,436
Daily Volume: 1,138
Performance Metrics
1 Week: -4.73%
1 Month: 8.53%
3 Months: 18.45%
6 Months: 12.65%
1 Year: -20.21%
YTD: 2.59%
Company Details
Employees: 70
Sector: Health technology
Industry: Biotechnology
Country:
Details
IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disorders and Alzheimer's disease. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.